J&j

J&J proposes paying $8.9 bn to settle baby talcum powder lawsuits

Johnson & Johnson is earmarking nearly USD 9 billion to cover allegations that its baby power containing talc caused cancer, more than quadrupling the amount that the company had previously set aside to pay for its potential liability. Under a proposal announced Tuesday, a J&J subsidiary will re-file for Chapter 11 bankruptcy protection and seek court approval for a plan that would result in one of the largest product-liability settlements in U.S. history. The USD 8.9 billion that J&J would transfer to the subsidiary, LTL Management, would be payable over the next 25 years. The amount is up from the USD 2 billion that the New Brunswick, New Jersey, company set aside in October 2021. The revised amount is being backed by more than 60,000 parties that have filed lawsuits alleging harm from J&J talcum powder, according to the company. J&J isn't admitting any wrongdoing as part of the proposed settlement, a point that company executive emphasised in a Tuesday statement

J&J forecasts strong profit, beats Wall Street estimates on pharma boost

Shares of the drugmaker were up nearly 1% at $170.28 in trading before the bell

Maharashtra FDA cancels manufacturing licence of J&J baby powder

The state government body also said that the use of the product may affect the health of the skin of newborn babies

Explained: What is the controversy around J&J's talc-based baby powder?

Johnson and Johnson (J&J) has been facing several thousand lawsuits from women who claim that they developed ovarian cancer after using the product

Johnson & Johnson to stop selling personal care products in Russia

(Reuters) -Johnson & Johnson said on Tuesday it would halt sale of personal care products in Russia, joining other companies that have limited their business in the country in response to its invasion of Ukraine.

Expert panel allows adolescent trials of J&J vaccine with riders

SEC asks J&J to monitor adverse events closely for next three months

J&J seeks FDA's approval for Covid-19 vaccine booster shot in adults

If authorized, J&J's booster could give millions more Americans additional protection against the coronavirus

India to make available 8 mn doses of J&J Covid vax: PM Modi at Quad Summit

India will make available 8 million doses of the Johnson and Johnson vaccine by the end of October under the Quad vaccine partnership, Foreign Secretary Harsh Vardhan Shringla on Friday informed.

Johnson & Johnson says Covid-19 booster shot is 94% effective

J&J said a booster given two months after the first dose increased antibody levels four to six-fold

J&J says coronavirus vaccine booster shot triggered an antibody surge

ignificant increases in antibody responses were seen in subjects ages 18 to 55 years old, and among those 65 or older who were given a lower dose of the booster.

Joaquin Duato set to replace Alex Gorsky as Johnson & Johnson's CEO

Duato, 59, currently serves as vice chairman of J&J's executive committee

India Coronavirus Dispatch: 2 in 5 districts yet to get RT-PCR testing lab

No clarity on the launch of single-dose J&J vaccine, over 60% doses given to rural population in last 3 weeks, and more-news relevant to India's fight against the pandemic

J&J seeks approval for single-dose Covid-19 vaccine in India

It is not clear whether J&J is seeking indemnity against adverse events following vaccination like its US peers

J&J says still in talks with Indian govt on Covid-19 vaccine

India had, in May, scrapped local trials for 'well-established' foreign coronavirus vaccines as it tried to hasten vaccination rollouts to fight a second wave of infections.

In talks with Pfizer, Moderna, J&J to make vaccines in India: Foreign secy

India is looking forward to WHO's nod for vaccine manufactured by Bharat Biotech

Covid-19 vaccination: Germany allows J&J, AstraZeneca jabs for all adults

Germany is making the one-shot Johnson & Johnson coronavirus vaccine available to all adults as it did with the AstraZeneca vaccine, though the bulk of the expected deliveries is still some way off. Germany has recommended the AstraZeneca shot mainly for over-60s because of a rare type of blood clot seen in an extremely small number of recipients. But amid a push to get as many people inoculated as possible, the government decided to allow doctors' offices to vaccinate any adults with it -- putting aside a priority system under which the oldest and most vulnerable have been vaccinated first. Health Minister Jens Spahn said authorities decided Monday to take the same approach with the Johnson & Johnson vaccine, about which there are similar concerns. He estimated that 5 to 6 million over-60s in Germany still need to be vaccinated and that should be concluded by early June. Spahn said the largest deliveries from Johnson & Johnson, more than 10 million doses, are expected in .

30 year old man in US hospitalised with clot after receiving J&J vaccine

A San Francisco Bay Area man in his 30s is recuperating after developing a rare blood clot in his leg within two weeks of receiving the Johnson & Johnson vaccine, University of California, San Francisco officials said. As of Friday, the US Centers for Disease Control and Prevention had reported the condition in 15 people, all women, after 8 million doses were administered nationally. It involves unusual clots that occur together with low levels of blood-clotting platelets. To the best of our knowledge, this is the first male patient with VITT syndrome in the US following the US emergency authorization of the Johnson & Johnson vaccine on February 27, 2021," UCSF said in a statement. US health officials lifted an 11-day pause on COVID-19 vaccinations using Johnson & Johnson's single-dose shot on Friday, after scientific advisers decided its benefits outweigh the rare risk of blood clot. Three of the women previously identified died, and seven remain hospitalised. The man is .

J&J to resume rollout of Covid-19 vaccine in Europe with safety warning

(Reuters) -Johnson & Johnson said on Tuesday it will resume rolling out its COVID-19 vaccine in Europe after the region's medical regulator said the benefits of the shot outweigh the risk of very rare, potentially lethal blood clots.

J&J, other drugmakers go to trial in US in $50 bn case over opioid abuse

J&J, Teva Pharmaceutical Industries Ltd, Endo International Plc and AbbVie's Allergan unit are alleged of fueling a drug crisis that according to the US government resulted in nearly 500,00 deaths

After US, South Africa suspends use of Johnson & Johnson Covid-19 vaccine

South African Health Minister Zweli Mkhize on Tuesday said that the country will be suspending the use of the Johnson & Johnson COVID-19 vaccine after health concerns raised by the US Food and Drug Administration (FDA)."We have determined to voluntarily suspend our rollout until the causal relationship between the development of clots and the Johnson and Johnson vaccine is sufficiently interrogated," Mkhize said in a statement."In the extremely unlikely event that Johnson and Johnson rollout is completely halted, we will not have any impediment to proceed with phase two of the rollout with Pfizer," he added.This comes after the US Centers of Disease Control and Prevention (CDC) and the FDA recommended a "pause" in the use of the Johnson and Johnson COVID-19 vaccine "out of an abundance of caution" over six reported cases in the US of a "rare and severe" type of blood clot.In a joint statement, the CDC and the FDA said they were investigating clots in six women in the days after .